Compare ATEC & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATEC | TLX |
|---|---|---|
| Founded | 1990 | 2015 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.3B |
| IPO Year | 2006 | N/A |
| Metric | ATEC | TLX |
|---|---|---|
| Price | $19.80 | $8.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 4 |
| Target Price | ★ $22.00 | $21.00 |
| AVG Volume (30 Days) | ★ 2.1M | 115.0K |
| Earning Date | 10-30-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.04 |
| Revenue | ★ $728,020,000.00 | $664,225,558.00 |
| Revenue This Year | $26.83 | N/A |
| Revenue Next Year | $16.61 | N/A |
| P/E Ratio | ★ N/A | $273.17 |
| Revenue Growth | 27.11 | ★ 55.35 |
| 52 Week Low | $8.70 | $8.76 |
| 52 Week High | $22.66 | $30.36 |
| Indicator | ATEC | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 46.75 | 34.46 |
| Support Level | $19.77 | $9.37 |
| Resistance Level | $21.42 | $10.03 |
| Average True Range (ATR) | 0.69 | 0.26 |
| MACD | -0.36 | -0.05 |
| Stochastic Oscillator | 6.54 | 2.25 |
Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.